Ecallantide for the Treatment of Hereditary Angiodema in Adults
Authors:
Open Access
- 1 January 2011
- journal article
- Published by SAGE Publications in Clinical Medicine Insights: Cardiology
- Vol. 5, CMC.S4434-54
Abstract
Hereditary angioedema (HAE) is a clinical disorder characterized by a deficiency of C1 esterase inhibitor (C1-INH). HAE has traditionally been divided into two subtypes. Unique among the inherited deficiencies of the complement system, HAE Types I and II are inherited as an autosomal dominant disorder. The generation of an HAE attack is caused by the depletion and/or consumption of C1-inhibitor manifested as subcutaneous or submucosal edema of the upper airway, face, extremities, or gastrointestinal tract mediated by bradykinin. Attacks can be severe and potentially life-threatening, particularly with laryngeal involvement and treatment of acute attacks in the United States has been severely limited. In December 2009 the FDA approved ecallantide for the treatment of acute HAE attacks. Ecallantide is a small recombinant protein acting as a potent, specific and reversible inhibitor of plasma kallikrein which binds to plasma kallikrein blocking its binding site, directly inhibiting the conversion of high molecular weight kininogen to bradykinin. Administered subcutaneously, ecallantide was demonstrated in two clinical trials, EDEMA3 and EDEMA4, to decrease the length and severity of acute HAE attacks. Although there is a small risk for anaphylaxis, which limits home administration, ecallantide is a novel, safe, effective and alternative treatment for acute HAE attacks.Keywords
This publication has 29 references indexed in Scilit:
- EcallantideNature Reviews Drug Discovery, 2010
- Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE)Journal of Allergy and Clinical Immunology, 2008
- Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitorJournal of Allergy and Clinical Immunology, 2007
- Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and CourseThe American Journal of Medicine, 2006
- Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedemaJournal of Allergy and Clinical Immunology, 2000
- Obtaining a family of high-affinity, high-specificity protein inhibitors of plasmin and plasma kallikreinMolecular Diversity, 1996
- Iterative Optimization of High-Affinity Protease Inhibitors Using Phage Display. 2. Plasma Kallikrein and ThrombinBiochemistry, 1996
- C1 Inhibitor and Hereditary Angioneurotic EdemaAnnual Review of Immunology, 1988
- Human C.hivin.1 inhibitor: primary structure, cDNA cloning, and chromosomal localizationBiochemistry, 1986
- Contribution of Plasma Protease Inhibitors to the Inactivation of Kallikrein in PlasmaJournal of Clinical Investigation, 1982